Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-β1, and TGF-β type II receptor interact to inhibit the growth of pituitary lactotropes

被引:47
|
作者
Sarkar, DK
Chaturvedi, K
Oomizu, S
Boyadjieva, NI
Chen, CP
机构
[1] Rutgers State Univ, Endorcrinol Program, Div Biomed, Ctr Alcohol Studies, New Brunswick, NJ 08901 USA
[2] Rutgers State Univ, Dept Anim Sci, New Brunswick, NJ 08901 USA
关键词
D O I
10.1210/en.2005-0430
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The neurotransmitter dopamine is known to inhibit prolactin secretion and the proliferation of lactotropes in the pituitary gland. In this study, we determined whether dopamine and TGF beta 1 interact to regulate lactotropic cell proliferation. We found that dopamine and the dopamine agonist bromocriptine stimulated TGF beta 1 secretion and TGF beta 1 mRNA expression but inhibited lactotropic cell proliferation both in vivo and in vitro. The dopamine's inhibitory action on lactotropic cell proliferation was blocked by a TGF beta 1-neutralizing antibody. We also found that PR1 cells, which express low amounts of the dopamine D2 receptor, demonstrated reduced expression of TGF beta 1 type II receptor and TGF beta 1 mRNA levels and had undetectable levels of TGF beta 1 protein. These cells showed a reduced TGF beta 1 growth-inhibitory response. Constitutive expression of the D2 receptor short isoform, but not the D2 receptor long isoform, induced TGF beta 1 and TGF beta 1 type II receptor gene expression and recovered dopamine- and TGF beta 1-induced growth inhibition in PR1 cells. The constitutive expression of D2 receptor short isoform also reduced the tumor cell growth rate. These data suggest that a TGF beta 1 system may mediate, in part, the growth-inhibitory action of dopamine on lactotropes.
引用
收藏
页码:4179 / 4188
页数:10
相关论文
共 50 条
  • [21] Serum level of transforming growth factor-β1 (TGF-β1) and the expression of TGF-β receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis
    Sakaguchi, K
    Kitano, M
    Nishimura, M
    Senoh, T
    Ohta, T
    Terao, M
    Shinji, N
    Koide, N
    Tsuji, T
    HEPATO-GASTROENTEROLOGY, 2004, 51 (60) : 1780 - 1783
  • [22] Expression of transforming growth factor(TGF)-Beta 1 and TGF type II receptor in the renal parenchyme of diabetic and nephrectomized rats
    Sol, MY
    Lee, KS
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 891A - 891A
  • [23] Co-transfection of hepatocyte growth factor and truncated TGF-β type II receptor inhibit scar formation
    Xu, Ji-Hua
    Zhao, Wan-Yi
    Fang, Qing-Qing
    Wang, Xiao-Feng
    Zhang, Ding-Ding
    Hu, Yan-Yan
    Zheng, Bin
    Tan, Wei-Qiang
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2020, 53 (01)
  • [24] Responsiveness to transforming growth factor-β (TGF-β)-mediated growth inhibition is a function of membrane-bound TGF-β type II receptor in human breast cancer cells
    Lynch, MA
    Petrel, TA
    Song, H
    Knobloch, TJ
    Casto, BC
    Ramljak, D
    Anderson, LM
    DeGroff, V
    Stoner, GD
    Brueggemeier, RW
    Weghorst, CM
    GENE EXPRESSION-THE JOURNAL OF LIVER RESEARCH, 2001, 9 (4-5): : 157 - 171
  • [25] TGFβ (transforming growth factor β) receptor type III directs clathrin-mediated endocytosis of TGFβ receptor types I and II
    McLean, Sarah
    Di Guglielmo, Gianni M.
    BIOCHEMICAL JOURNAL, 2010, 429 : 137 - 145
  • [26] Transforming growth factor β (TGF-β)-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-β function
    Wang, SE
    Wu, FY
    Shin, I
    Qu, SM
    Arteaga, CL
    MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (11) : 4703 - 4715
  • [27] Soluble transforming growth factor β type II receptor attenuates TGF-β1 activity in human colorectal cancer LoVo cells
    Zhou, Rui
    Xiong, Bin
    Song, Haibin
    Liu, Shiquan
    Wang, Xinbo
    ONCOLOGY REPORTS, 2008, 20 (06) : 1449 - 1456
  • [28] Transforming growth factor-β (TGF-β) is not involved in growth inhibition of human keratinocytes by 1α, 25(OH)2D3:: A study with adenoviral vector expressing a truncated TGF-β type II receptor (AdexCATβTR).
    Hanakawa, Y
    Shirakata, Y
    Yamasaki, K
    Sayama, K
    Ueno, H
    Hashimoto, K
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 623 - 623
  • [29] Mutant p53 attenuates the SMAD-dependent transforming growth factor β1 (TGF-β1) signaling pathway by repressing the expression of TGF-β receptor type II
    Kalo, Eyal
    Buganim, Yosef
    Shapira, Keren E.
    Besserglick, Hilla
    Goldfinger, Naomi
    Weisz, Lilach
    Stambolsky, Perry
    Henis, Yoav I.
    Rotter, Varda
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (23) : 8228 - 8242
  • [30] Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5)
    Callahan, JF
    Burgess, JL
    Fornwald, JA
    Gaster, LM
    Harling, JD
    Harrington, FP
    Heer, J
    Kwon, C
    Lehr, R
    Mathur, A
    Olson, BA
    Weinstock, J
    Laping, NJ
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (05) : 999 - 1001